Breaks Categories: News

ThursdayFeb 27, 2025 9:58 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Report Q4 and Full-Year 2024 Results on March 13

HeartBeam (NASDAQ: BEAT) announced it will release its fourth quarter and full-year 2024 financial results on March 13, 2025, and host a conference call at 4:30 p.m. ET. The call will include updates on regulatory initiatives, commercial-readiness efforts, and key milestones. CEO Robert Eno and CFO Timothy Cruickshank will lead the discussion, followed by a Q&A session. A corresponding presentation will be available via the company’s investor relations website. To view the full press release, visit https://ibn.fm/nxla9 About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is.…

Continue Reading

WednesdayFeb 26, 2025 11:30 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and efforts to maintain its Nasdaq listing. The company reported a strengthened financial position, with $14 million in cash as of Feb. 26, 2025, expected to fund operations into the first quarter of 2026. CNS remains on track to announce primary data analysis for its global Berubicin trial in the first half of 2025 and plans to begin its TPI 287 clinical program by enrolling its first patient before year-end. To maintain compliance with Nasdaq’s listing…

Continue Reading

WednesdayFeb 26, 2025 9:27 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, announced that the underwriter of its recent public offering exercised its option to purchase an additional 864,033 shares at $1.70 per share. This move increases the total gross proceeds from the offering to approximately $11.5 million, before deductions. The exercise of the over-allotment option closed Feb. 25, 2025, following the initial 5,882,353 share offering that closed Feb. 14, 2025. The funds will support HeartBeam’s strategic growth initiatives, including U.S. commercialization efforts, R&D, and regulatory projects. MDB Capital served as the underwriter, with Paulson Investment Company LLC acting as…

Continue Reading

TuesdayFeb 25, 2025 9:30 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Partners with APST Research to Advance ALS Drug Approval Process

Clene (NASDAQ: CLNN) has entered into an agreement with Germany-based APST Research GmbH to utilize its extensive neurofilament light chain (NfL) database in FDA-recommended analyses of CNM-Au8® for treating amyotrophic lateral sclerosis (ALS). APST's repository includes biomarker data from over 4,300 ALS patients, which will help Clene compare NfL changes in NIH-sponsored Expanded Access Protocol participants to matched controls. The results could support Clene’s planned New Drug Application submission for CNM-Au8 under the FDA's Accelerated Approval pathway in the second half of 2025. CEO Rob Etherington emphasized the importance of leveraging real-world evidence to advance potential treatments for ALS. To view…

Continue Reading

MondayFeb 24, 2025 9:23 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern University/Northwestern Memorial Hospital is recruiting for its Phase 1B/2 clinical trial of "CLD-101" in newly diagnosed high-grade glioma patients. The company completed shipment of the first batch of CLD-101—comprising allogeneic neural stem cells loaded with the oncolytic adenovirus CRAd-S-pk7—to support the trial, which builds on promising Phase 1 results in 12 patients published in The Lancet Oncology. The physician-led and NCI-sponsored study, headed by Dr Maciej Lesniak and Dr Roger Stupp and funded by the NIH/NCI SPORE, aims to evaluate a multiple-dose regimen that could…

Continue Reading

FridayFeb 21, 2025 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management will also be available for one-on-one meetings with registered investors, and a video webcast of the presentation will be accessible on-demand through the conference presenters portal. To view the full press release, visit https://ibn.fm/yGKfB About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central…

Continue Reading

ThursdayFeb 20, 2025 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry peers to follow the company in 2025. The presentation focused on CNS Pharmaceuticals’ advancements in developing treatments for primary and metastatic brain and central nervous system cancers, emphasizing its strategic initiatives and clinical progress for the year ahead. To view the full press release, visit https://ibn.fm/3gUjC About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic…

Continue Reading

WednesdayFeb 19, 2025 10:49 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials

Annovis Bio (NYSE: ANVS) will host a live webcast on Feb. 27, 2025, at 4:30 p.m. EST, where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families regarding the company’s clinical trials and future plans. The forum will provide updates on the ongoing Phase 3 Alzheimer’s disease trial, plans for the Phase 3 Parkinson’s disease study, and patient communication strategies. A brief presentation will precede a Q&A session, with attendees encouraged to submit questions in advance. The event underscores Annovis’ commitment to patient engagement and transparency. To view the full press release, visit https://ibn.fm/aFJV6 About Annovis Bio…

Continue Reading

WednesdayFeb 19, 2025 10:33 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-50 Reverse Stock Split

CNS Pharmaceuticals (NASDAQ: CNSP) announced a 1-for-50 reverse stock split of its common stock, set to take effect on Feb. 21, 2025. The company’s shares will continue trading on Nasdaq under the symbol “CNSP” but with a new CUSIP number: 18978H409. The reverse split aims to increase the per-share trading price and ensure compliance with Nasdaq’s minimum share price requirement. As a result, every 50 shares of common stock will be consolidated into one, with proportional adjustments made to outstanding equity awards and warrants. No fractional shares will be issued, with cash payments provided instead. The number of authorized shares…

Continue Reading

TuesdayFeb 18, 2025 12:46 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will present on Feb. 20 at 10:45 a.m. ET, discussing novel formulations of anthracyclines and taxanes designed to cross the blood-brain barrier. The company’s lead candidate, Berubicin, has completed patient enrollment in a pivotal study against glioblastoma, with primary analysis data expected in the first half of 2025. CNS Pharmaceuticals is also advancing TPI 287 and plans to engage with the FDA on trial design. Berubicin has received Fast Track and Orphan Drug…

Continue Reading